1. Oncologist-Directed Solutions for Cancer Therapy & Drug Discovery
CERTIS ONCOLOGY SOLUTIONS
Oncologist-Directed Solutions for Cancer Therapy & Drug Discovery
Privileged & Confidential Do not distribute without permission Copyright © Certis Oncology Solutions, 2019

2. Copyright © Certis Oncology Solutions, 2019
Our Mission
Our Mission
Certis Oncology Solutions was formed in 2016 with the mission to provide individualized precision patient care. Our patient-directed therapy enables oncologists to tailor and optimize therapies for patients suffering from aggressive cancers. We also provide pre-clinical services for pharmaceutical and biotech companies. The differentiators for all of our services are the Certis Orthotopic PDX techniques.
Copyright © Certis Oncology Solutions, 2019

3. Highest Establishment Rates are in Untreated HG Tumors
Our Mission
Highest Establishment Rates are in Untreated HG Tumors
Prior Treatment Negatively Correlates with Xenograftability
Copyright © Certis Oncology Solutions, 2019

4. Copyright © Certis Oncology Solutions, 2019
Clinical Concordance
Our Mission
Copyright © Certis Oncology Solutions, 2019

5. PDX In Vivo Pharmacology Studies to Direct Clinical Management
Our Mission
Copyright © Certis Oncology Solutions, 2019

6. Over 300 Tumors Received and 40 Publications
Our Mission
Copyright © Certis Oncology Solutions, 2019

7. Copyright © Certis Oncology Solutions, 2019
CLIA Certified
Our Mission
November 2017 – Submitted
May 2018 – Registered
March 2019 – Passed On-site inspection
Zero deficiencies
Copyright © Certis Oncology Solutions, 2019

8. Copyright © Certis Oncology Solutions, 2019
Available PDX Models
Operations
PDX Number
Indication
Category
PDX259
Triple Negative Breast
Breast
PDX256
Colorectal (Liver Metastasis)
Colon
PDX264
Colorectal
PDX278
PDX287
PDX296
PDX304
PDX292
Gastric
PDX295
Lung (Hip Metastasis)
Lung
PDX024
Melanoma
PDX132
PDX134
PDX148
PDX001
Undifferentiated Pleomorphic Sarcoma
Sarcoma
PDX011
Follicular Dendridic Sarcoma
PDX025
Liposarcoma
PDX061
Pleomorphic sarcoma with rhabdomyosarcomatous differentiation
PDX064
Pleomorphic liposarcoma
PDX077
Pleomorphic Sarcoma
PDX103
Leiomyosarcoma
PDX172
Mxyofibrosarcoma
PDX210
Osteosarcoma
PDX257
Ewing's Sarcoma
PDX261
Recurrent Liposarcoma
PDX263
PDX265
PDX276
Radiation-associated Sarcoma
PDX288
Copyright © Certis Oncology Solutions, 2019

9. Triple Negative Breast PDX
Operations
58F BRCA1+ with untreated left breast mass.
Invasive ductal carcinoma, grade 3, PR-, ER weak positive, HER2 IHC equivocal.
Copyright © Certis Oncology Solutions, 2019

10. Copyright © Certis Oncology Solutions, 2019
Ewing’s Sarcoma PDX
Operations
63M Ewing’s Sarcoma from right humerus
EWSR1-FLI1 Fusion
Copyright © Certis Oncology Solutions, 2019

11. Copyright © Certis Oncology Solutions, 2019
In Vivo Pharmacology – PDX257 Ewing’s Sarcoma
Operations
Confidential
Copyright © Certis Oncology Solutions, 2019

12. Copyright © Certis Oncology Solutions, 2019
Colorectal PDX
Operations
39 M – colorectal carcinoma from liver metastasis
14 gauge core needle biopsy from liver
Copyright © Certis Oncology Solutions, 2019

13. Copyright © Certis Oncology Solutions, 2019
PDX278 – CRC Liver Met
Operations
Day 1
Day 15
Copyright © Certis Oncology Solutions, 2019

14. Copyright © Certis Oncology Solutions, 2019
PDX278 – CRC Liver Met
Operations
Primary Implant
Vasculature
Primary Implant
Copyright © Certis Oncology Solutions, 2019

15. Models in Development Operations PDX Indication Category PDX
Squamous Cell Carcinoma
Skin
PDX012
Leiomyosarcoma
Sarcoma
PDX031
PDX038
PDX039
PDX043
PDX103
PDX120
PDX173
PDX181
PDX007
Myxofibrosarcoma
PDX042
Spindle Cell Sarcoma
PDX034
GIST
PDX010
PDX017
PDX018
NOS
PDX020
PDX028
UPS
PDX059
PDX061
Pleomorphic sarcoma with rhabdomyosarcomatous differentiation
PDX073
PDX077
HG Pleomorphic Sarcoma w Myogenic differentiation
PDX093
Osteosarcoma
PDX117
Chordoma
PDX149
Non Otherwise Specified Sarcoma
PDX167
Metastatic Carcinoma
PDX138
PDX143
Chondrosarcoma, de-differentiated, grade 3
PDX150
PDX172
PDX174
Metastatic Osteosarcoma
PDX183
PDX202
Malignant Peripheral Nerve Sheath
PDX009
Well-diff/de-diff Liposarcoma
PDX045
PDX055
Pleomorphic Liposarcoma Carcinoma
PDX083
Dediff Liposarcoma
PDX108
Myxoid Liposarcoma
PDX
Indication
Category
PDX158
Dediff Liposarcoma
Sarcoma
PDX188
Well Diff Liposarcoma
PDX165
Intramuscular myxoma
PDX008
Ewing's Sarcoma
PDX206
PDX025
PDX054
Well-diff/de-diff Liposarcoma
PDX064
Pleomorphic Liposarcoma
PDX142
PDX177
PDX190
Liposarcoma
PDX193
PDX199
SD-Mry
PDX109
Synovial Sarcoma
PDX205
Undifferentiated Pleomorphic Sarcoma
PDX211
Spindle Cell Sarcoma
PDX169
NOS malignant undifferentiated small round blue cell neoplasm
PDX203
Non Otherwise Specified Sarcoma
PDX-Bsarc
Sarcoma Sarcoma
SD031
Pancreatic (metastatic)
Pancreatic
MDA AC2
MDA AC5
PTAX39
PTAX52
PTAX70
AA-316
PDX063
Melanoma
PDX107
PDX160
Metastatic Melanoma
SD032
Gastric Carcinoma
Gastric
274BMC
Colorectal
CT1
SD034
SD039
Colon Adenocarcinoma Carcinoma
SD058
SD062
Cce

16. Copyright © Certis Oncology Solutions, 2019
Newly Acquired Models
Operations
Glioblastoma
Pancreatic
Colorectal
Ovarian
Breast
Lung
Melanoma
Copyright © Certis Oncology Solutions, 2019